The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

GLP-1 drugs also improve blood flow to the heart ... and therefore a positive effect in Alzheimer’s disease and Parkinson’s disease,” note the authors. More than 100 preclinical research ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

GLP-1 drugs also improve blood flow to the heart and act directly ... memory formation and therefore a positive effect in Alzheimer’s disease and Parkinson’s disease,” note the authors. More than 100 ...